Longitudinal antibody profiling after dengue reveals distinct dynamics by antibody specificity over 18 months (opens in new tab)

The four dengue virus serotypes (DENV1-4) co-circulate worldwide, posing major challenges for vaccine development. One key issue is that certain levels and subsets of cross-reactive antibodies have been associated with enhanced disease during subsequent infection with a different DENV serotype. To understand the heterogeneity of DENV antibody responses and delineate their distinct kinetics, we define the magnitude and kinetics of 84 antiviral antibody subsets (by isotype, subclass, antigen, a...